RegeneRx, G-treeBNT deal

The companies formed a JV to develop RegeneRx’s RGN-259 to treat dry eye and neurotrophic keratitis in the U.S. G-treeBNT will be responsible for conducting and funding R&D through the approval of the NDA. RegeneRx granted the JV an exclusive license to commercialize RGN-259 in the U.S., and the biotech contributed non-clinical and clinical data already generated. G-treeBNT will hold a majority stake, which will increase when developmental milestones are completed.

RegeneRx may participate in key development and commercialization decisions and will receive $1 million in two tranches. The company is also eligible for royalties ranging from high single-digits to low double-digits. ...